Seattle Genetics And Astellas Announce Updated Results From Phase 1b/2 Trial Of PADCEV; After Median Follow-Up, 73% Of Patients Had Confirmed Tumor Response With Majority Of Responses Still Ongoing, No New Safety Signals Observed